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ABSTRACT 27
The cell wall glucosaminidase LytB of Streptococcus pneumoniae is a surface exposed 28
protein involved in daughter cell separation, biofilm formation and contributes to 29
different aspects of the pathogenesis process. In this study we have characterized the 30
antibody responses after immunization of mice with LytB in the presence of alhydrogel 31
as an adjuvant. Enzyme-linked immunosorbent assays measuring different subclasses of 32
immunoglobulin G, demonstrated that the antibody responses to LytB were 33
predominantly IgG1 and IgG2b, followed by IgG3 and IgG2a subclasses. Complement-34
mediated immunity against two different pneumococcal serotypes was investigated 35
using sera from immunized mice. Immunization with LytB increased the recognition of 36
S. pneumoniae by complement components C1q and C3b demonstrating that anti-LytB 37
antibodies trigger activation of the classical pathway. Phagocytosis assays showed that 38
serum containing antibodies to LytB stimulates neutrophil-mediated phagocytosis 39
against S. pneumoniae. Animal models of infection including invasive pneumonia and 40
sepsis were performed with two different clinical isolates. Vaccination with LytB 41
increased bacterial clearance and induced protection demonstrating that LytB might be a 42
good candidate to be considered in a future protein-based vaccine against S. 43
pneumoniae.44
45
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1. Introduction 50
Streptococcus pneumoniae is one of the leading etiologic agents of community-51
acquired pneumonia, sepsis and bacterial meningitis particularly affecting children and 52
elderly adults [1, 2]. Prevention of invasive pneumococcal disease (IPD) is one of the 53
leading priorities in public health due to the high morbidity and mortality rates 54
worldwide, especially in children in developing countries [3]. Current prophylactic 55
measures against pneumococcal infection are based on polysaccharide-containing 56
vaccines that may be conjugated to a carrier protein in order to elicit protection in 57
children [4]. However, one of the major disadvantages of these polysaccharide vaccines 58
is the extensive variability among the pneumococcal population with up to 96 different 59
capsular polysaccharides (CPS) described to date [5]. An additional limitation is that 60
capsular switching appeared after the introduction of pneumococcal conjugate vaccines 61
(PCVs), which results in a serious concern because these strains may emerge by 62
avoiding vaccine-induced immunity due to acquisition of capsular genes from non-63
vaccine serotypes [6-8]. To circumvent these problems, efforts are being made to 64
investigate S. pneumoniae protein-based candidate vaccines that may protect against 65
different serotypes. In this study we investigated the cell wall hydrolase LytB of S. 66
pneumoniae as a potential vaccine candidate. LytB is located at sites close to the polar 67
ends of the cell and is surface exposed. This enzyme has N-acetylglucosaminidase 68
activity and plays an essential role in daughter cell separation [9, 10].  69
In terms of pathogenesis, LytB participates in biofilm formation, attachment to 70
human epithelial cells and contributes to sepsis and pneumonia by increasing the ability 71
of LytC to avoid complement-mediated immunity and phagocytosis [11-13]. From the 72
prophylactic perspective, LytB might be a promising target for the development of a 73
universal pneumococcal vaccine because an anti-LytB antiserum significantly protected 74
4 
mice from a lethal challenge with different pneumococcal strains [14]. In this study we 75
show that immunization with LytB is immunogenic and enhances complement-76
mediated immunity and phagocytosis of different serotypes of S. pneumoniae. As a 77
consequence, vaccination using LytB increases bacterial clearance and induces 78
protection against pneumococcal sepsis and invasive pneumonia.  79
80
2. Materials and methods 81
2.1. Bacterial strains 82
S. pneumoniae clinical isolates used in this study included strain 957 (serotype 3; 83
amoxicillin MIC = 0.015 µg ml1; erythromycin MIC = 0.25 µg ml1, levofloxacin MIC 84
= 1 µg ml1, tetracycline MIC = 0.5 µg ml1, chloramphenicol MIC = 4 µg ml1) and 85
strain 48 (serotype 23F; amoxicillin MIC = 16 µg ml1; erythromycin MIC > 128 µg 86
ml1, levofloxacin MIC = 1 µg ml1, tetracycline MIC = 64 µg ml1, chloramphenicol 87
MIC = 4 µg ml1). Pneumococcal isolates were cultured on blood agar plates at 37 °C in 88
5% CO2 or in Todd-Hewitt broth supplemented with 0.5% yeast extract to an optical 89
density at 580 nm (OD580) of 0.4 (approximately 108 colony-forming units (CFU) ml1) 90
and stored at 70 °C in 10% glycerol as single-use aliquots.  91
2.2. Vaccination experiments in mice 92
BALB/c mice were bred by the Instituto de Salud Carlos III (ISCIII) animal facility. 93
All mice used were 8–16 weeks old and, within each experiment, groups of mice were 94
matched for age and sex. Animal experiments were performed at ISCIII in accordance 95
with Spanish legislation (RD 1201/2005) and EU regulations (218/63/EU). The animal 96
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experiments performed in this work were approved by the Animal Care and Use 97
Committee of ISCIII (CBA PA 52_2011-v2 and PROEX 218/15). 98
The pneumococcal LytB protein used for immunization studies was purified as 99
previously described [9, 10] and was prepared for animal inoculations at 20–40 g in 100
Alum (Alhydrogel; aluminum hydroxide, InvivoGen) as the adjuvant in a 1:1 101
proportion. Groups of 5 mice were immunized by intraperitoneal (IP) inoculation of 200 102
l of Alum alone or 200 l of LytB protein preparation in Alum adjuvant on days 0, 7, 103
and 14 as previously described [15]. Animals were euthanized on day 21 and blood was 104
collected from cardiac puncture and conserved as pooled for further in vitro assays. For 105
protection experiments against sepsis, groups of 10 mice were immunized as previously 106
described, followed by IP challenge on day 21 with 103 CFU/ per mouse of serotype 3 107
strain or 107 CFU per mouse of serotype 23F strain representing at least the lethal dose 108
50 (LD50) of each strain for sepsis infection. The immunization schedule for protection 109
against pneumonia was the same as before although the bacterial challenge was 110
performed by the intranasal route with 50 l of 104 CFU/mouse of serotype 3 strain or 5 111
 107 CFU/mouse of serotype 23F strain representing at least the LD50 of each strain for 112
pneumonia. Bacterial counts were determined during the first 24–48 h from blood 113
samples (6 l per mouse) obtained from the tail vein of infected animals as previously 114
described [16]. The development of disease was monitored daily, and mice were 115
sacrificed when they exhibited severe signs of disease.  116
2.3. Enzyme linked immunosorbent assays to detect Ig subclasses 117
Specific antibody titers in pooled sera from five mice of each group were measured 118
by enzyme-linked immunosorbent assays (ELISA) using 96-well polystyrene Maxisorp 119
plates (Nunc) coated with 0.5 g of purified LytB protein for 2 h at 37 °C and blocked 120
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with a PBS–2% bovine serum albumin (BSA) solution as previously described [17]. 121
Bound antibodies were detected by using horseradish peroxidase (HRP)-conjugated 122
goat anti-mouse IgG, IgG1, IgG2a, IgG2b, IgG3 and IgA; Santa Cruz) for 30 min and 123
developed using o-phenylenediamine (Sigma-Aldrich) before determining the OD492 124
using a microtiter plate reader (Anthos 2020). 125
2.4. Activation of complement immunity 126
Complement activation was assessed using flow cytometry assays, as described 127
before [17-19]. Briefly, C3b deposition was analyzed by incubating 5  106 CFU of S. 128
pneumoniae in 10 µl of serum (diluted to 50% in PBS) for 30 min at 37C using pooled 129
sera from mice immunized with Alum alone or immunized with LytBAlum. Bacteria 130
were then incubated for 30 min on ice with fluorescein isothiocyanate (FITC)-131
conjugated polyclonal goat anti-mouse C3b antibody (ICN-Cappel) diluted 1/300 in 132
PBS. Then, bacteria were fixed in 3% paraformaldehyde and analyzed on a FACS 133
Calibur flow cytometer (BD Biosciences) using forward and side scatter parameters to 134
gate on at least 25,000 cells. This assay was adapted for C1q binding incubating for 1 h 135
with rabbit anti-mouse C1q antibody (Abcam) followed by an additional incubation 136
with FITC-conjugated polyclonal goat anti-rabbit IgG. The results were expressed as a 137
relative percent fluorescence index (RFI) that measures not only the proportion of 138
fluorescent bacteria positive for the host serum component investigated but also the 139
intensity of fluorescence that quantify the immune component bound [19, 20].  140
2.4. Opsonophagocytosis  141
Phagocytosis was evaluated using a flow cytometry assay including S. pneumoniae142
strains described above labeled with 5, 6-carboxyfluorescein succinimidyl ester (FAM-143
7 
SE; Molecular Probes) and human HL-60 cells (CCL-240; ATCC) differentiated to 144
granulocytes. The general conditions of the assay were based on those described 145
previously except that clinical isolates of serotype 3 and 23F were incubated with 146
pooled sera from mice immunized with Alum alone or immunized with the mixture 147
LytBAlum [16, 21]. Infection assays were performed with a ratio of 10 bacteria per 148
cell. A minimum of 6,000 cells were analyzed using a FACS Calibur flow cytometer. 149
Results were expressed as a RFI defined as the proportion of positive cells for 150
fluorescent bacteria multiplied by the geometric mean of fluorescence intensity, which 151
correlates with the amount of bacteria phagocytosed per cell. 152
153
2.5. T cell response  154
Experiments investigating cellular populations of lymphocytes were performed in 155
non-immunized mice and in mice immunized with Alum alone or vaccinated with LytB 156
mixed with Alum as explained above. Briefly, single-cell suspensions of the spleens of 157
each group, were prepared in staining buffer (2% fetal calf serum in PBS). Detection of 158
CD3, CD4 and CD8 was performed using standard protocols with the following 159
antibodies diluted 1/300 in staining buffer (Armenian hamster anti-mouse CD3-160
phycoerythrin (PE), Tonbo; rat anti-mouse CD4-FITC, Biolegend; rat anti-mouse CD8-161
PE, Tonbo). Cells were analyzed on a FACSCalibur flow cytometer.  162
2.6. Gene lytB sequence accession numbers 163
The LytB nucleotide sequences of clinical isolates 48 (serotype 23F) and 957 164
(serotype 3) have been deposited in the GenBank databases. They have been assigned 165
accession numbers KX151143 and KX151145, respectively. The multiple alignment of 166
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the LytB glucosaminidases from these clinical isolates in comparison to the LytB of 167
D39 (serotype 2) and TIGR4 (serotype 4) strains is shown in Supplemental Fig. 1. 168
2.7. Statistical analysis 169
Data are representative of results obtained from at least three independent 170
experiments, and each data point represents the mean and standard deviations (SD) for 3 171
to 5 replicates. Statistical analysis was performed by using two-tailed Student’s t test 172
(for two groups), whereas analysis of variance (ANOVA) followed by a Dunnett’s post 173
hoc test was chosen for multiple comparisons. Survival was analyzed by the log-rank 174
test. GraphPad InStat version 6.0 (GraphPad Software, San Diego, CA) was used for 175
statistical analysis. Differences were considered statistically significant with P <0.05 (*) 176
and highly significant with P <0.01 (**) and P <0.001 (***).  177
178
3. Results 179
3.1. Antibody response to LytB180
The predominant IgG subclass responses after vaccination with LytB were assessed 181
using ELISA specific for murine sera including total IgG, IgG1, IgG2a, IgG2b and 182
IgG3. Antibody levels were investigated in normal mouse serum (NMS) from naïve 183
(non-immunized) mice or sera from mice immunized with Alum alone or with LytB 184
mixed with Alum. Sera from mice immunized with LytB elicited strong IgG levels 185
compared to Alum alone and NMS groups (Fig. 1A). Vaccination with LytB induced 186
consistent levels of IgGs predominantly of subclasses IgG1 and IgG2b followed by 187
IgG3 and IgG2a (Fig. 1). Overall, these results indicated that pneumococcal LytB is an 188
immunogenic protein that induces IgG antibodies of different subclasses that might be 189
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functional in terms of host-immune response. Immunization with LytB by the IP route 190
induced a certain level of IgA in blood compared to immunization with Alum alone and 191
NMS (Fig. 1F). However, the importance of this immunoglobulin in host defense 192
against pneumococcus, may be more relevant for mucosal immunity rather than 193
systemic immunity.  194
3.2. Complement activation mediated by antibodies to LytB  195
The complement system is an important component of the host immune response 196
against invading pathogens such as S. pneumoniae. Complement immunity is strongly 197
initiated by IgG antibodies leading to the activation of the classical pathway which is 198
the dominant cascade for complement activation against S. pneumoniae [18, 22]. 199
Recognition by C1q, the first component of the classical pathway, was investigated 200
using pneumococcal strains of two different serotypes and pooled sera from mice 201
immunized with Alum alone or with LytBAlum (Fig. 2). Incubation of pneumococcal 202
clinical isolates with sera containing specific antibodies to LytB increased the 203
recognition by C1q indicating that immunization with LytB triggers activation of the 204
classical pathway against S. pneumoniae (Fig. 2). In addition, C3b deposition on the 205
pneumococcal surface was significantly enhanced in the presence of anti-LytB 206
antibodies (Fig. 3). Taken together, these results demonstrates that vaccination with 207
LytB induces complement-mediated responses against S. pneumoniae (Fig. 2 and 3). 208
3.3. Immunization with LytB induces opsonophagocytosis of S. pneumoniae209
Antibodies raised against LytB activate the opsonization process and may contribute 210
to host defense by improving opsonophagocytosis (OP). We investigated this possibility 211
by using a flow cytometry assay measuring the uptake of pneumococcal clinical isolates 212
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mediated by HL-60 cells differentiated to granulocytes, which is a cell line widely used 213
for measuring protection by current PCVs [21]. For these assays, FAM-SE-labeled S. 214
pneumoniae strains were incubated with sera from mice immunized only with Alum or 215
with LytB mixed with Alum. As negative controls, we included bacteria incubated with 216
Hank’s balanced salt solution (HBSS) to evaluate the phagocytosis level without serum 217
components. In the absence of complement (HBSS control), phagocytosis was reduced 218
compared to Alum group and markedly impaired compared to LytB immune sera, 219
which confirmed the importance of complement components in phagocytosis mediated 220
by antibodies to LytB (Fig. 4). The level of phagocytosis was significantly higher when 221
antibodies to LytB were present in comparison to Alum group, confirming that 222
immunization with LytB stimulates phagocytosis of S. pneumoniae. 223
3.4. Antibodies against LytB increases bacterial chain length 224
The impact of immunization with LytB on the morphology of S. pneumoniae was 225
investigated. For this assay, the clinical isolate of serotype 23F was incubated for 4 h at 226
37C with different sera including NMS, sera from mice immunized with Alum or sera 227
from mice vaccinated with Alum in the presence of 20 g of LytB, as previously 228
described. Incubation of S. pneumoniae with NMS (diluted 1/200) or sera from mice 229
immunized with Alum (diluted 1/200) showed the typical diplococcal morphology (Fig. 230
5A and B). However, incubation with sera containing specific antibodies to LytB 231
(diluted 1/200) increased chain formation with pneumococcal cells displaying short and 232
long chains compatible with an altered cell separation pattern (Fig. 5C). This phenotype 233
of altered morphology mediated by LytB antibodies was also observed with a dilution 234
of serum of 1/2000 (data not shown). 235
236
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3.5. Vaccination with LytB did not modify the T cell response. 237
Activation of the cellular response after immunization with antigenic proteins might 238
be protective against pneumococcal infection. For this purpose, groups of mice were 239
immunized with Alum or with LytB mixed with Alum as described above, and after 240
three immunizations, mice were culled and the spleen was obtained for detection of 241
CD3, CD4 and CD8 lymphocytes. These results confirmed that vaccination with LytB 242
did not affect the proportion of different T cell populations in comparison to 243
immunization with Alum or with non-immunized mice (Fig. 6).244
3.6. Immunization with LytB protects mice against S. pneumoniae infection 245
IPD is a devastating infectious process associated to high mortality rates that mainly 246
affects the elderly and children. The protective activity of LytB against IPD was 247
investigated in a sepsis model of infection caused by clinical isolates of S. pneumoniae248
belonging to serotypes 3 and 23F (Fig. 7). Vaccination with 20 g of LytB decreased 249
bacterial counts in blood at 48 h in comparison to Alum group and increased survival 250
rates against sepsis caused by the serotype 3 strain (Fig. 7A and B). Mice immunized 251
with 40 g of LytB during three weeks (three doses) and infected with the serotype 3 252
strain, showed increased protection against sepsis caused by this clinical isolate with 253
protective rates of 70% in the LytB-vaccinated group vs 10% in the Alum group (P 254
<0.01) (Fig. 7C). In addition, a significant reduction in the bacterial load at 24 and 48 h 255
was observed in the blood of mice immunized with LytB (Fig. 7D). Protection against 256
sepsis mediated by LytB was also tested using a serotype 23F strain. Vaccination with 257
20 g of LytB increased survival and decreased bacterial counts in blood (Fig. 7E and 258
F) confirming that LytB might be a promising vaccine candidate against sepsis caused 259
by S. pneumoniae.  260
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Pneumonia is a leading cause of mortality worldwide killing more children than 261
AIDS, measles and malaria combined [3, 23]. Hence, protection against pneumococcal 262
pneumonia induced by immunization with LytB was analyzed. Mice were vaccinated 263
with 20 g of LytB during three weeks (three doses) and infected by the intranasal route 264
with a lethal dose of S. pneumoniae of serotypes 3 or 23F (Fig. 8). Increased survival 265
rates were observed against pneumonia produced by serotype 3 strain ranging from 40% 266
in the vaccinated group with LytB vs no protection in the Alum group (Fig. 8A). The 267
higher survival conferred by vaccination with LytB was associated with a significant 268
reduction in the bacterial levels in the blood in comparison to mice immunized only 269
with Alum (Fig. 8B). These experiments were repeated using a serotype 23F strain 270
confirming that immunization with LytB significantly increased the survival (P <0.01) 271
showing a 70% protection in the group vaccinated with LytB vs 10% in the Alum group 272
(Fig. 8C). Again, vaccination with LytB increased the bacterial clearance of S. 273
pneumoniae from the systemic circulation (Fig. 8D) strongly suggesting that LytB 274
might be a promising vaccine candidate against pneumococcal pneumonia and invasive 275
disease. 276
4. Discussion 277
Several pneumococcal proteins are currently under investigation as alternative 278
vaccine candidates that may overcome the limitations of vaccines based on CPS [24]. In 279
this study we have characterized the immunological responses and the protective effect 280
of the cell wall hydrolase LytB as a promising pneumococcal protein vaccine. LytB 281
belongs to the choline-binding family of proteins in which several members including 282
PspA, PspC, PcpA or LytA, have been proposed as vaccine candidates [25-28]. LytB, 283
despite showing certain polymorphism in the number of choline-binding repeats, is a 284
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well-conserved protein among S. pneumoniae clinical isolates [29]. Sequence analysis 285
of the LytB glucosaminidase from the two clinical isolates of this study were compared 286
to LytBD39 and LytBTIGR4 (Supplemental Fig. 1). Our results show that the LytB of the 287
clinical isolate of serotype 3 lacks two choline-binding repeats compared to the LytB of 288
strains 48 (serotype 23F) and D39 (serotype 2). However, the LytB of strains 48 and 289
D39 are very similar. Immunization was performed using alhydrogel as adjuvant or with 290
LytB mixed with alhydrogel since this adjuvant has been approved for human use in 291
studies evaluating pneumococcal proteins [30, 31]. Vaccination with LytB induced a 292
strong IgG response of different subclasses including IgG1, IgG2a, IgG2b, and IgG3. 293
This is important because some of these subtypes of IgGs are elicited by current human 294
vaccine formulations such as the 23-valent pneumococcal polysaccharide vaccine 295
(PPSV) and PCVs. In this regard, the antibody response conferred by PPSV is 296
predominantly of the IgG2 subclass [32, 33]. The magnitude of the serotype-specific 297
IgG response to PCVs varies by serotype, vaccine formulation and age [34]. In adults, 298
PCVs induce primarily an IgG2 response whereas in children the predominant response 299
is of the IgG1 subclass [33, 35, 36]. The specific IgG subclass generated is relevant 300
from the functional perspective as IgG1 and IgG3 antibodies fix complement and bind 301
Fc receptors more efficiently than IgG2 [37-39]. Immunization with LytB induced high 302
levels of these immunoglobulins suggesting that antibodies to this protein might activate 303
complement-mediated phagocytosis (22). In this sense, differences in the expression of 304
Ig isotypes between human and mice have been previously reported and direct 305
correlation between subtypes within classes in these species are difficult to make 306
because they are not directly equivalent [40]. However, despite the difficulty in 307
comparing the findings derived from studies of murine Ig responses to humans, these 308
studies can be useful in the characterization of novel protein antigens for vaccine 309
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development by increasing  the understanding of protective immune mechanisms 310
against pneumococcal infection. 311
Experiments exploring complement activation on the surface of two different clinical 312
isolates demonstrated that antibodies to LytB increased the recognition by C1q and C3b 313
demonstrating that vaccination with LytB triggers classical pathway activation. This is 314
critical in terms of pneumococcal infection as this pathway has been shown to be vital 315
for complement activation to S. pneumoniae in humans and mice [18, 22]. Host defense 316
against pneumococcus depends on opsonophagocytosis [1, 41] with neutrophils the 317
important players in the immune response, as neutropenia is highly associated to 318
increased susceptibility to pneumococcal infection [42, 43]. In this study, using a cell 319
line differentiated into neutrophils, we show that immunization with LytB increased 320
complement-mediated phagocytosis confirming that antibodies to LytB activate the 321
phagocytosis process against S. pneumoniae. Generation of an IgG3 response by LytB 322
immunization may be relevant against systemic infection as this immunoglobulin is 323
highly protective against a fatal pneumococcal infection [44]. An additional explanation 324
for the increased complement-dependent phagocytosis mediated by antibodies to LytB 325
is due to morphological changes they induce in bacteria. This is important because LytB 326
is essential for cellular separation at the end of cell division as pneumococcal strains 327
lacking LytB form long chains instead of typical diplococci [9, 10]. This is important 328
because chain formation in S. pneumoniae via antibody-mediated agglutination has been 329
shown to be relevant to enhance complement-mediated recognition and phagocytosis 330
[45]. Our results show that antibodies to LytB increased bacterial size inducing 331
chaining, which is compatible with enhanced susceptibility to complement-mediated 332
phagocytosis and impaired virulence [45, 46].  333
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The protective role of LytB was explored in murine models of sepsis and pneumonia. 334
Vaccination with LytB protected against pneumococcal sepsis and invasive pneumonia 335
caused by clinical isolates of serotypes 3 or 23F. Hence, the presence of antibodies to 336
LytB controlled bacterial replication in the bloodstream reducing the severity of the 337
infection process in both serotypes. This is relevant from the prophylactic perspective of 338
serotype 3 strains as IPD cases due to this serotype have not decreased after the 339
introduction of the current PCVs [47]. Furthermore, lack of clinical efficacy against 340
serotype 3 isolates following PCV administration has been associated to impaired 341
immune response and the abundance of CPS produced by these strains [48]. In addition, 342
the relative failure of protection induced by current PCV-13 against serotype 3 isolates 343
has been recently linked to the release of type 3 CPS by these isolates interfering with 344
antibody-mediated killing and protection by anti-CPS antibodies [49]. In this sense, our 345
study shows that immunization with LytB increased complement-mediated 346
phagocytosis and bacterial clearance in the systemic circulation, protecting against 347
pneumococcal sepsis and pneumonia caused by a serotype 3 strain. The results of this 348
study suggest that LytB is a promising vaccine candidate to be considered perhaps in a 349
combined cocktail with other antigens, as combinations of pneumococcal proteins can 350
provide additive or synergistic effects that may be beneficial [24, 50, 51]. Alternatively, 351
the use of LytB as a carrier protein for type 3 CPS might be a prophylactic strategy to 352
increase the immunogenicity against this serotype as combinations of pneumococcal 353
proteins conjugated to CPS included in PCVs are being evaluated [52]. Overall, our 354
study confirms the potential benefit of LytB as a protein vaccine antigen against 355
pneumococcal pneumonia and invasive disease. 356
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Figure Legends 534
535
Fig. 1. Antibody levels after immunization with Alum or LytB. ELISA was used to 536
analyze the antibody levels including total IgG (A), IgG1 (B), IgG2a (C), IgG2b (D), 537
IgG3 (E) and IgA (F). Specific antibodies were measured in normal mouse serum (gray 538
circles), pooled sera from mice immunized with Alum as adjuvant (gray squares) and 539
pooled sera from mice immunized with 20 g of LytB mixed with Alum (black 540
triangles). Error bars represent the SDs and asterisks indicate statistical significance of 541
LytB immunization compared to the Alum group. * P< 0.05; **, P<0.01; ***, P<0.001. 542
543
Fig. 2. Classical pathway activation mediated by antibodies against LytB. (A) 544
Deposition of mouse C1q on the surface of a serotype 3 clinical isolate using pooled 545
sera from mice immunized with Alum (gray bar) or with LytB mixed with Alum (black 546
bar). (B) Example of a flow cytometry histogram for C1q deposition on a serotype 3 547
strain. (C) Recognition of a clinical isolate of serotype 23F by mouse C1q using pooled 548
sera from mice immunized with Alum (gray bar) or with LytB mixed with Alum (black 549
bar). (D) Example of a flow cytometry histogram for C1q deposition on a serotype 23F 550
strain. Results are expressed as a relative % fluorescence index (RFI). Error bars 551
represent the SDs and asterisks indicate statistical significance of LytB immunization 552
compared to the Alum group. * P< 0.05; **, P<0.01; ***, P<0.001. 553
554
Fig. 3. Recognition of S. pneumoniae by C3b using pooled sera from mice immunized 555
with Alum (grey bars) or pooled sera from mice immunized with LytB mixed with 556
Alum (black bars). (A) Deposition of mouse C3b on the surface of a serotype 3 clinical 557
isolate. (B) Example of a flow cytometry histogram for C3b deposition on serotype 3 558
25 
strain. (C) Recognition of a clinical isolate of serotype 23F by mouse C3b. (D) Example 559
of a flow cytometry histogram for C3b deposition on serotype 23F strain. Results are 560
expressed as a relative % fluorescence index. Error bars represent the SDs and asterisks 561
indicate statistical significance of LytB immunization compared to the Alum group. * 562
P< 0.05; **, P<0.01; ***, P<0.001. 563
564
Fig. 4. Opsonophagocytosis (OP) assays using the HL-60 neutrophil cell line and S. 565
pneumoniae strains incubated with HBSS (open bars), or pooled sera from mice 566
immunized with Alum (gray bars) or with LytB mixed with Alum (black bars). (A) OP 567
of a serotype 3 clinical isolate. (B) Example of a flow cytometry histogram for OP of 568
serotype 3 strain. (C) OP of serotype 23F clinical isolate. (D) Example of a flow 569
cytometry histogram for OP of serotype 23F strain. Error bars represent the SDs and 570
asterisks indicate statistical significance of LytB immunization compared to the Alum 571
group. * P< 0.05; **, P<0.01; ***, P<0.001. 572
573
Fig. 5. Phase-contrast microscopy images of the pneumococcal clinical isolate of 574
serotype 23F exposed for 4 h at 37C to different murine sera. (A) Normal mouse serum 575
from naïve mice. (B) Pooled sera from mice immunized with Alum. (C) Pooled sera 576
from mice immunized with 10 g of LytB mixed with Alum. Bars, 25 m. 577
578
Fig. 6. T cell response represented as proportion of CD3, CD4 and CD8 in non-579
immunized mice (white bars), mice immunized with Alum (gray bars) or mice 580
immunized with LytB mixed with Alum (black bars). Error bars represent the SDs. 581
Experiments were repeated three times. 582
26 
Fig. 7. Protection against pneumococcal sepsis after vaccination with Alum (black dots) 583
or with LytB mixed with Alum (black triangle). (A) Survival against sepsis caused by 584
the clinical isolate 957 of serotype 3 in mice immunized with Alum or with 20 g of 585
LytB. (B) Bacterial counts in blood at 24 h and 48 h from mice immunized with Alum 586
or 20 g of LytB and infected with strain 957 of serotype 3. (C) Survival after sepsis 587
caused by clinical isolate 957 of serotype 3 in mice immunized with Alum or LytB (40 588
g). For differences in survival between Alum group and LytB group (**P <0.01, Log-589
rank test) (D) Bacterial counts in blood at 24 h and 48 h from mice immunized with 590
Alum or LytB (40 g) and infected with strain 957 of serotype 3. (E) Survival after 591
sepsis caused by clinical isolate 48 of serotype 23F in mice immunized with Alum or 592
with LytB (20 g). (F) Bacterial counts in blood at 24 h and 48 h from mice immunized 593
with Alum or LytB (20 g) and infected with strain 48 of serotype 23F. Error bars 594
represent the SDs and asterisks indicate statistical significance of LytB immunized 595
group compared to the Alum group. * P< 0.05; **, P<0.01; ***, P<0.001. 596
597
Fig. 8. Protection against pneumococcal pneumonia after vaccination with Alum (black 598
dots) or with LytB (20 g) mixed with Alum (black triangle). (A) Survival after 599
pneumonia caused by a clinical isolate of serotype 3. (B) Bacterial counts in blood at 24 600
h and 48 h from mice infected with serotype 3 strain. (C) Survival after pneumonia 601
caused by a clinical isolate of serotype 23F. (D) Bacterial counts in blood at 24 h and 48 602
h from mice infected with serotype 23F strain. Error bars represent the SDs and 603
asterisks indicate statistical significance of LytB immunized group compared to the 604
Alum group. * P< 0.05; **, P<0.01; ***, P<0.001. 605
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